TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Oreja Guevara, Celia ^a,b   Ramos Cejudo, Jaime ^a   Aroeira, Luiz S ^a   Chamorro, Beatriz ^a   Diez Tejedor, Exuperio ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Cytokines; Glatiramer acetate; Multiple sclerosis; Natalizumab; Th1; Th2

Indexed keywords

GAMMA INTERFERON; GLATIRAMER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; TH1 TH2 BALANCE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CYTOKINES; HUMANS; MALE; MULTIPLE SCLEROSIS; PEPTIDES; RECURRENCE; TH1-TH2 BALANCE; TREATMENT OUTCOME;

EID: 84866306371     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-95     Document Type: Article

References (39)

1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747. 10.1146/annurev.immunol.23.021704.115707, 15771584.
2. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004, 61:1613-1615. 10.1001/archneur.61.10.1613, 15477521.
3. Hamann I, Zipp F, Infante-Duarte C. Therapeutic targeting of chemokine signaling in Multiple Sclerosis. J Neurol Sci 2008, 274:31-38. 10.1016/j.jns.2008.07.005, 18706659.
4. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006, 27:48-55. 10.1016/j.tips.2005.11.002, 16310865.
5. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002, 2:933-944. 10.1038/nri954, 12461566.
6. Segal BM. Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr Allergy Asthma Rep 2003, 3:86-93. 10.1007/s11882-003-0017-6, 12543000.
7. Vartanian T, Li Y, Zhao M, Stefansson K. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med 1995, 1:732-743. 2230017, 8612196.
8. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991, 325:467-472. 10.1056/NEJM199108153250704, 1852181.
9. Miller A, Glass-Marmor L, Abraham M, Grossman I, Shapiro S, Galboiz Y. Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin Neurol Neurosurg 2004, 106:249-254. 10.1016/j.clineuro.2004.02.008, 15177778.
10. Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005, 106:163-177. 10.1016/j.pharmthera.2004.11.007, 15866318.
11. Steinman L, Conlon P. Antigen specific immunotherapy of multiple sclerosis. J Clin Immunol 2001, 21:93-98. 10.1023/A:1011020225433, 11332658.
12. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276. 10.1212/WNL.45.7.1268, 7617181.
13. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M, Ferrari A, Sormani MP, Ottonello C, Levrero F, Uccelli A, Bruzzi P. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998, 50:1127-1133. 10.1212/WNL.50.4.1127, 9566406.
14. Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. J Neurol Sci 2004, 222:65-73. 10.1016/j.jns.2004.04.012, 15240198.
15. Sellner J, Greeve I, Findling O, Kamm CP, Minten C, Engelhardt B, Grandgirard D, Leib SL, Mattle HP. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis. Neurochem Int 2008, 53:17-21. 10.1016/j.neuint.2008.04.004, 18524417.
16. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler 2008, 14:622-630. 10.1177/1352458507087136, 18424480.
17. Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 2007, 6:469-475. 10.1016/j.autrev.2007.02.003, 17643935.
18. Sega S, Wraber B, Mesec A, Horvat A, Ihan A. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 2004, 106:255-258. 10.1016/j.clineuro.2004.02.010, 15177779.
19. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000, 105:967-976. 10.1172/JCI8970, 377485, 10749576.
20. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005, 4:567-575. 10.1016/S1474-4422(05)70167-8, 16109363.
21. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then BF, Dose T, Wekerle H, Hohlfeld R. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000, 97:7452-7457. 10.1073/pnas.97.13.7452, 16566, 10861011.
22. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003, 170:4483-4488.
23. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:15-23. 10.1056/NEJMoa020696, 12510038.
24. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. 10.1056/NEJMoa044397, 16510744.
25. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guerette C, Antel JP, Fournier A, Grand"Maison F, Bar-Or A. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006, 59:748-754. 10.1002/ana.20859, 16634035.
26. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005, 64:1336-1342. 10.1212/01.WNL.0000158329.30470.D0, 15851719.
27. Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 2010, 16:208-217. 10.1177/1352458509355068, 20007431.
28. Ramos-Cejudo J, Oreja-Guevara C, Stark AL, de Rodriguez AL, Chamorro B, Diez-Tejedor E. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J Clin Immunol 2011, 31:623-631. 10.1007/s10875-011-9522-x, 3155864, 21491095.
29. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846. 10.1002/ana.20703, 16283615.
30. Farina C, Then BF, Albrecht H, Meinl E, Yassouridis A, Neuhaus O, Hohlfeld R. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001, 124:705-719. 10.1093/brain/124.4.705, 11287371.
31. Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler 2007, 13:754-762. 10.1177/1352458506074510, 17613604.
32. Weder C, Baltariu GM, Wyler KA, Gober HJ, Lienert C, Schluep M, Radu EW, De LG, Kappos L, Duda PW. Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis. Eur J Neurol 2005, 12:869-878. 10.1111/j.1468-1331.2005.01084.x, 16241976.
33. Tumani H, Kassubek J, Hijazi M, Lehmensiek V, Unrath A, Sussmuth S, Lauda F, Kapfer T, Fang L, Senel M, Brettschneider J. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Eur Neurol 2011, 65:164-169. 10.1159/000324035, 21372576.
34. Khademi M, Stol D, Olsson T, Wallstrom E. Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. Eur J Neurol 2008, 15:309-312. 10.1111/j.1468-1331.2007.02037.x, 18190511.
35. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, Sellebjerg F, Olsson T. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009, 16:528-536. 10.1111/j.1468-1331.2009.02532.x, 19220425.
36. Kivisakk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, Khoury SJ. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009, 72:1922-1930. 10.1212/WNL.0b013e3181a8266f, 2690969, 19487650.
37. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375-381. 10.1056/NEJMoa051847, 15947078.
38. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008, 70:1150-1151.
39. Schiess N, Calabresi PA. Natalizumab: bound to rebound?. Neurology 2009, 72:392-393. 10.1212/01.wnl.0000341783.33962.5b, 19188569.